Article Details
Retrieved on: 2021-07-29 18:11:15
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
“This agreement with Byondis highlights the potential of our GlycoTarget discovery and technology platform,” said Henner Kollenberg, managing ...
Article found on: www.biopharminternational.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here